Brought to you by 
Replidyne reverse merges with Cardiovascular Systems
13 Nov 2008
Executive Summary
Right after withdrawing from its initial public offering, Cardiovascular Systems Inc. announced it has agreed to be acquired by infectious disease therapeutics developer Replidyne in a reverse merger. Once the stock swap is completed, CSI's shareholders will own 83% of the combined company, which will retain CSI's name.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Replidyne reverse merges with Cardiovascular Systems
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice